Gilead’s Sofosbuvir Heads To FDA Advisory Panel; Novelty Seems Main Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
While the nucleoside polymerase inhibitor class for hepatitis C has faced significant safety issues, analysts say FDA’s main concern likely will center on how best to treat patients with genotype 3 of the virus.